Sutro Biopharma, Inc
111 Oyster Point Blvd
South San Francisco
About Sutro Biopharma, Inc
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently under investigation in a Phase 1 clinical trial for patients with advanced B-cell malignancies, and was granted Orphan Drug Designation by the FDA for multiple myeloma. STRO-002, a folate receptor alpha (FolRα)-targeting ADC, is currently being investigated in a Phase 1 clinical trial for patients with ovarian and endometrial cancers and was granted Fast Track designation by the FDA for ovarian cancer. A third product candidate, CC-99712, a BCMA-targeting ADC, which is part of Sutro’s collaboration with Bristol Myers Squibb, formerly Celgene Corporation, is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma and has received Orphan Drug Designation from the FDA. A fourth product candidate, M1231, a MUC1-EGFR, first-in-class bispecific ADC, which is part of Sutro’s collaboration with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), is enrolling patients for its Phase 1 clinical trial of patients with metastatic solid tumors, non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma. These four product candidates above being evaluated in clinical trials resulted from Sutro’s XpressCF® and XpressCF+™ technology platforms. Bristol Myers Squibb and EMD Serono have worldwide development and commercialization rights for CC-99712 and M1231, respectively, for which Sutro is entitled to milestone or contingent payments and tiered royalties.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro’s platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.
The platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.
Stock Symbol: STRO
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies.
138 articles with Sutro Biopharma, Inc
Sutro Biopharma, Inc. today announced that Chief Executive Officer, Bill Newell , will participate in two upcoming virtual investor conferences.
11/19/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Heidi Hunter, accomplished healthcare leader and President of Cardinal Health Specialty Solutions, to bring additional global biopharma strategic and operational expertise to Sutro's Board.
Sutro Biopharma, Inc. today announced that Chief Executive Officer, Bill Newell , will participate in three upcoming virtual investor conferences.
Sutro Biopharma, Inc. and BioNova Pharmaceuticals Limited today jointly announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate (ADC), for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck
Sutro Biopharma, Inc. today announced that Merck has extended the research term for the first cytokine derivative program under the 2018 Merck Agreement, for an additional two years.
Sutro Biopharma, Inc. announced that on September 15, 2021, the Compensation Committee of Sutro's Board of Directors granted restricted stock unit awards representing an aggregate of 150,000 shares of Sutro common stock and stock options to purchase an aggregate of 145,000 shares of Sutro common stock to 3 new employees.
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced the appointment of two executives to the Company's leadership team.
With multiple job openings across the industry, biotech and biopharma employers have to come up with different strategies to retain top talent.
Sutro Biopharma, Inc. today announced that Bill Newell , Chief Executive Officer, will participate in the 2021 Wells Fargo Securities Healthcare Conference during a virtual fireside chat on Thursday, September 9, at 3:20 p.m. ET / 12:20 p.m. PT.
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
Sutro Biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRα).
8/13/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported its financial results for the quarter ended June 30, 2021, its recent business highlights, and provided a preview of anticipated selected milestones in the second half of 2021.
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced the appointment of Jane Chung to the newly-created position of Chief Commercial Officer, effective August 9, 2021.
Sutro Biopharma, Inc. announced that Chief Executive Officer, Bill Newell, will participate in a panel titled "ADCs – Take Me to Your Tumor" at the 12th Annual Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, at 2:20 p.m. ET / 11:20 a.m. PT.
Sutro Biopharma, Inc. today announced that Chief Executive Officer, Bill Newell , will participate in two virtual investor conferences in June.
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany
Sutro Biopharma, Inc. announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, related to a patient enrollment achievement in the Phase 1 dose escalation and expansion study of M1231 in adult patients with metastatic solid tumors, including non-small cell lung cancer and esophageal squamous cell carcinoma.
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
- Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months - One patient achieved a CR and nine patients achieved a PR, of which four were confirmed PRs. Median duration of response on the five confirmed responders was 5.8 months - Data on STRO-002 from the dose-escalation cohort to be presented as a poster at ASCO and available as part of the Company Corporate Presentation has a cut-off date of April 23, 2021
If these companies are any indication, it appears that the biopharma industry will be a hybrid of virtual and physical workforces, and with this comes a whole new set of risks.